Dante Labs – Saudi Mirror http://www.saudimirror.com News On-line Wed, 22 Jun 2022 08:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=5.3.2 Dante Genomics partners with Emirates Post to deliver advanced genomic services in UAE http://www.saudimirror.com/dante-genomics-partners-with-emirates-post-to-deliver-advanced-genomic-services-in-uae/ Wed, 22 Jun 2022 08:00:00 +0000 http://www.saudimirror.com/?p=214715 NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) — Emirates Post, the official postal operator and leading express provider in the UAE, has partnered with Dante Genomics, a global leader in genomics and precision medicine, to facilitate the availability of advanced genomic services across the UAE in line with the nation's vision of making healthcare testing accessible to everyone in the country.

The partnership follows the recent launch of Dante Genomics' office and operations in the UAE. According to the agreement, Emirates Post will collect and drop off testing kits from Dante Labs to customers across the UAE, in addition to designating Emirates Post Customer Happiness Centers as a point of sale and drop off/collection point for the testing kits. Genetic testing provides personalized information about one's overall wellbeing to empower them to live a healthier lifestyle.

Peter Somers, CEO of Emirates Post, said: "We are delighted that Dante Genomics entrusted us to support the expansion of their advanced genomic services across the UAE. This partnership further highlights the seamless services we provide to customers through our delivery network, which is the largest in the country. With its customer–centric and diverse choice of services, Emirates Post is an ideal delivery partner for companies looking for expansion and sustainable solutions to even the remotest parts of the country. Our exemplary services have enabled us to build trust and meet all the requirements of our customers and partners."

Andrea Riposati, Group CEO of Dante Genomics, said that universal access to healthcare requires the universal operations that Emirates Posts has built. "Together, we can deliver advanced genomics everywhere. We are honored to partner with Emirates Post on logistics and distribution of advanced genomic services in the UAE. Emirates Post has proven a fantastic partner with a clear vision of how to democratize access to goods, services and technology for all people in the UAE," he added.

Dante Genomics is a global leader in genome sequencing with the best technology in the healthcare industry to provide personalized preventive healthcare solutions by offering next–generation diagnostic and prevention tools directly to consumers and healthcare professionals. With the use of proprietary software and patented technologies and leveraging cutting edge sequencers such as the Illumina NovaSeq 6000 and the PacBio Sequel IIe, Dante Genomics has delivered the benefits of the genome to individuals and clinics in 97 countries.

About Dante Genomics

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

About Emirates Post Group

Emirates Post Group Company is a Public Joint Stock Company under Emirates Investment Authority (EIA) operating as a commercial entity across the emirates. It manages the planning of its postal operational division and subsidiaries, which consist of Emirates Post – the leading postal and express delivery provider in the region, Wall Street Exchange, Instant Cash, and the Electronic Documents Centre. The Dubai–based Company is the official entity responsible for licensing all postal, courier and logistics services within the UAE.

Contact:

Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantelabs.com


GLOBENEWSWIRE (Distribution ID 8576564)

]]>
GetFIT Lifestyle partners with Dante to bring the power of genomics to the world of fitness http://www.saudimirror.com/getfit-lifestyle-partners-with-dante-to-bring-the-power-of-genomics-to-the-world-of-fitness/ Mon, 06 Jun 2022 13:30:00 +0000 http://www.saudimirror.com/?p=213950 "" Collaboration unveiled at the RiminiWellness conference on June 3, 2022 ""

MILAN, Italy, June 06, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, partners with GetFIT Lifestyle, the first Italian fitness group, to offer Dante's Scientific Fitness Reports to the more than 30,000 GetFIT Lifestyle members. The goal of this partnership is to personalize an individual's physical exercise routine based on their genetic needs rather than the traditional approach based on superficial physical characteristics or taste, ushering in a new frontier of health where genetics meets the world of fitness.

Beginning July 1, 2022, GetFIT will offer Scientific Fitness Reports within its fitness clubs to the more than 30,000 active members and all interested parties exclusively in Italy and Europe. Genetic variants are differences in DNA between people. The Dante Genomics report explains how specific genetic variants in one's DNA can influence one's physical aptitude and metabolism, making this an extremely useful diagnostic tool now and in the future.

The information obtained from the analysis of the genes of an individual will for the first time the ability to formulate a plan with the support of the GetFIT certified instructors to optimize a training regimen in an effective and healthy way with the goal to live a longer, healthier and more energetic life.

“We are excited to partner with GetFIT on this progressive collaboration to bring valuable genomic information to the world of fitness," said Andrea Riposati, CEO of Dante Genomics. "At Dante, we often say "personalized medicine needs personalized data,' and I am confident that our innovative genomic tests will mean a more personalized fitness regimen and training plan for all GetFIT customers uniquely tailored to their DNA."

“For almost 40 years, the GetFIT Group has been taking care of people's well–being. Present in Milan since 1984 with its fitness centers with swimming pools and thermarium and over 30,000 active members, our Mission is to inspire people to choose and maintain a healthy and active lifestyle and to feel good about themselves, through paths suitable for everyone and designed on the needs of each one," said Livio Leardi, GetFIT Founder. "Being able to participate as a partner of Dante in this innovative project will give our team the opportunity to create even more effective and personalized training programs, based on the characteristics of the individual person. This makes us proud to say that we have taken another step towards our goal: to highlight the importance of the symbiotic relationship between health and physical activity.”

Both companies presented the project at a press conference held at RiminiWellness last week.

About GetFIT Lifestyle
GetFIT is the first Italian fitness group with clubs in the city of Milan, Italy with over 30,000 active members. Through multifunctional, spacious and bright spaces, fitness rooms and swimming pools that coexist with thermarium and relaxation areas, GetFIT clubs are the ideal place to find fun, energy and relaxation. We select and train with passion all our team that represents with great professionalism our care for the reception and health of the body. We offer cutting–edge activities and design personalized paths to accompany our members towards the achievement of their goals. We have always chosen leading partners in the sector to take care of the well–being of the Milanese.

About Dante Genomics
Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:
Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com


GLOBENEWSWIRE (Distribution ID 8566435)

]]>
Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery http://www.saudimirror.com/dante-labs-highlights-advancements-to-its-drug-discovery-development-program-demonstrating-the-value-of-genomic-data-to-drug-discovery/ Thu, 26 May 2022 11:30:00 +0000 http://www.saudimirror.com/?p=214347 NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company's pipeline, applying Dante's internal siRNA and mRNA technology to rare and common diseases.

Since the company's foundation, Dante has invested in a robust R&D program with the goal to create end–to–end solutions from diagnosis to therapy. Dante's program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante's pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co–development to achieve validation and partner externally on clinical trials and commercialization.

"Personalized medicine needs personalized data, and our progress in the last 18 months alone demonstrates the value of genomic data to research and discovery drug development," said Andrea Riposati, CEO of Dante Genomics. "When we founded Dante Genomics, we felt we had a responsibility to deliver personalized medicine beyond diagnosis so that no patient would be facing a diagnosis with no effective treatments. It is this holistic approach that challenges and motivates us as a company to accelerate science to save more lives."

Dante has advanced its internal drug programs in muscle rare disease and neurological rare disease into the pre–clinical phase. The newest addition to Dante's discovery program pipeline is an mRNA oncology therapeutic in the molecular discovery phase meant to strengthen the immune system against certain cancer types. In co–development with US biotechnology company Protelica, Dante has therapies in respiratory disease and ovarian cancer, both in the non–regulatory pre–clinical phase.

Dante's mRNA COVID vaccine program development began in early 2021 and has recently completed the regulatory pre–clinical phase and is ready for its first in–human.

"My academic background has taught me the value of RNA therapeutics, and Dante's internal R&D leverages mRNA and siRNA technology to accelerate time to patients from concept to clinic," said Mattia Capulli, Chief Scientific Officer of Dante Genomics. "The data and advanced timeline of our mRNA vaccine program demonstrates Dante's high quality RNA platform and the reproducibility of this model applied to other clinical therapies.

The Company also announced its rebrand to Dante Genomics to better reflect its global efforts in genomic information and personalized medicine. The company name, Dante Genomics, comes from the compound of humanity and science. "Dante" refers to the Italian humanitarian poet and "Genomics" refers to the powerful science that takes place in a genomics lab. Since its foundation, Dante Genomics has delivered hundreds of thousands of people with affordable, quality genomic solutions to inform their healthcare decisions. The Company's holistic approach to medicine spans from sequencing and variant interpretation to discovery drug development.

About Dante Genomics

Dante Genomics is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

Contact:

Laura D'Angelo
VP of Investor Relations
ir@dantelabs.com
+39 0862 191 0671
www.dantegenomics.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5e163117–b6e3–40cc–8ecc–48cd9d72e8ce


GLOBENEWSWIRE (Distribution ID 8560383)

]]>
Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab Emirates (UAE) http://www.saudimirror.com/mainz-biomed-dante-labs-announce-partnership-for-the-commercialization-of-coloalert-in-europe-and-the-united-arab-emirates-uae/ Thu, 19 May 2022 07:01:00 +0000 http://www.saudimirror.com/?p=213846
  • Dante Labs is a Global Leader in Genomics and Precision Medicine
  • Mainz is Exclusively Focused on Developing Next Generation Diagnostics for the Early Detection of Cancer
  • BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz" or the "Company"), a molecular genetics diagnostic company specializing in the early detection of cancer and Dante Labs, a global leader in genomics and precision medicine, announced today a partnership for the commercialization of ColoAlert in Italy and the United Arab Emirates (UAE). ColoAlert is Mainz's flagship product, a highly efficacious and easy to use at–home detection test for colorectal cancer (CRC).

    Dante Labs is a global leader in genome sequencing with a product development and commercial franchise focused on providing personalized preventive healthcare solutions by leveraging its robust databases and proprietary software platform to offer next–generation diagnostic tools direct to consumers and healthcare professionals. Inherent to Dante Lab's business model is managing state–of–the–art genomic sequencing laboratories in multiple international regions, and operating a robust e–commerce platform.

    "As a young company with the goal of bringing to market important diagnostic tools to help treat and prevent cancer indications, it's an absolute pleasure to partner with an industry leader such as Dante Labs," commented Guido Baechler, Chief Executive Officer of Mainz Biomed. "Our differentiated commercial plan of partnering with third–party laboratories for test kit processing versus the traditional methodology of operating a single facility requires alliances with like–minded companies such as Dante Labs, who share our passion for forward–thinking diagnostic test development and marketing strategies."

    The partnership will first launch ColoAlert in Italy and UAE using Dante's various established commercial channels. Samples will initially be processed at Mainz's in–house facility and then Dante will purchase Mainz's CE–IVD polymerase chain reaction (PCR) assay kits and transition all test processing to Dante's wholly–owned automated genomic sequencing laboratories in Italy (Europe) and Dubai (UAE) to offer localized service and support.

    "We are excited by the opportunity to align with Mainz and represent ColoAlert in these initial markets," commented Andrea Riposati, Chief Executive Officer of Dante Labs. "Both the product and the Company mirror our mission to develop and market top–tier preventive health solutions and use new channels to make innovative tests available to more patients around the world. With the launch of our enhanced ecommerce platforms for advanced diagnostics, ColoAlert is an amazing product to deliver more personalized medicine."

    ColoAlert is currently marketed across Europe, and the partnership with Dante Labs marks the test's initial launch in the Middle East. Mainz will continue to develop commercial and R&D partnerships with companies that lead the field of health screening with a particular focus on stool diagnostics.

    About ColoAlert

    ColoAlert detects colorectal cancer (CRC) via a simple–to–administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*. The test utilizes proprietary methods to analyze cell DNA for specific tumor markers combined with the fecal immunochemical test (FIT) and is designed to detect tumor DNA and CRC cases in their earliest stages. The product is CE–IVD marked (complying with EU safety, health and environmental requirements) and is transitioning to compliance with IVDR. The product is commercially available in a selection of countries in the Europe Union. Mainz Biomed currently distributes ColoAlert through a number of clinical affiliates. Once approved in the U.S., the Company's commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.

    *Dollinger MM et al. (2018)

    About Colorectal Cancer

    Colorectal cancer (CRC) is the second most lethal cancer in the U.S. and Europe, but also the most preventable with early detection providing survival rates above 90%. Annual testing costs per patient are minimal, especially when compared to late–stage treatments of CRC which cost patients an average of $38,469 per year. The American Cancer Society estimated that in 2021 there were approximately 149,500 new cases of colon and rectal cancer in the U.S. with 52,980 resulting in death. Recent FDA decisions suggest that screening with stool DNA tests such as ColoAlert in the US should be conducted once every three years starting at age 45. Currently there are 112 million Americans aged 50+, a total that is expected to increase to 157 million within 10 years. Appropriately testing these US–based 50+ populations every three years as prescribed equates to a US market opportunity of approximately $3.7 Billion per year.

    About Mainz Biomed N.V.

    Mainz Biomed develops market–ready molecular genetic diagnostic solutions for life–threatening conditions. The Company's flagship product is ColoAlert, an accurate, non–invasive, and easy–to–use early detection diagnostic test for colorectal cancer. ColoAlert is currently marketed across Europe with FDA clinical study and submission process intended to be launched in the first half of 2022 for U.S. regulatory approval. Mainz Biomed's product candidate portfolio includes PancAlert, an early–stage pancreatic cancer screening test based on Real–Time Polymerase Chain Reaction–based (PCR) multiplex detection of molecular–genetic biomarkers in stool samples, and the GenoStick technology, a platform being developed to detect pathogens on a molecular genetic basis.

    For more information please visit www.mainzbiomed.com

    For media enquiries, please contact press@mainzbiomed.com

    For investor enquiries, please contact ir@mainzbiomed.com

    About Dante Labs
    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantelabs.com

    Forward–Looking Statements

    Certain statements made in this press release are "forward–looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward–looking statements may be identified by the use of words such as "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward–looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward–looking statements. Due to known and unknown risks, actual results may differ materially from the Company's expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward–looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID–19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the "SEC") by the Company. Additional information concerning these and other factors that may impact the Company's expectations and projections can be found in its initial filings with the SEC, including its Prospectus filed on October 12, 2021 and amended on October 25, 2021 and November 1, 2021 as well as the Prospectus filed on January 21, 2022. The Company's SEC filings are available publicly on the SEC's website at www.sec.gov. Any forward–looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward–looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.


    GLOBENEWSWIRE (Distribution ID 8545842)

    ]]>
    Dante Labs receives grant by Italian government to pilot revolutionary CE-IVD, clinical whole genome sequencing-based Citizen Test for a G7 country, starting a new era in clinical genomics http://www.saudimirror.com/dante-labs-receives-grant-by-italian-government-to-pilot-revolutionary-ce-ivd-clinical-whole-genome-sequencing-based-citizen-test-for-a-g7-country-starting-a-new-era-in-clinical-genomics/ Tue, 10 May 2022 11:30:00 +0000 http://www.saudimirror.com/?p=213994 NEW YORK, May 10, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the Italian Ministry of Economic Development has selected Dante to develop and pilot the first fully–CE–IVD, clinically approved whole genome sequencing (WGS) test for the citizens of Italy to be named the Dante Citizen Test.

    The goal of the project is to introduce clinical whole genome sequencing with clinical reports in the standard medical care of the country's hospitals and healthcare system and is the first step to introduce whole genome sequencing in the national healthcare system of a European and G7 country. The test will leverage Dante's proprietary Extensa software for reporting, interpretation and analysis of whole genome and medical data.

    "Clinical whole genome sequencing will finally become a standard solution in public healthcare systems, not as a luxury for the few but as a right for every citizen, thanks to the Dante Citizen Test," said Andrea Riposati, CEO of Dante Labs. "The effective use of whole genome sequencing in standard clinical care requires mastery at sequencing, interpretation and integration of medical information, at scale. This is what we have been doing at Dante. Now, with partnerships with forward looking governments, like Italy's, we can impact millions of patients worldwide."

    The groundbreaking project will be overseen by the Dante's newly appointed European Medical Genomics Board, which is made of national and multinational world leaders in genomics, including geneticists, molecular biochemists and clinical experts in pharmacogenomics, nutrigenomics and oncogenomics, prenatal, neonatal and pediatric rare diseases.

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantelabs.com


    GLOBENEWSWIRE (Distribution ID 8538985)

    ]]>
    Dante Labs selected to provide genetic testing for Abu Dhabi Stem Cells Center, jointly developing mRNA cancer vaccines http://www.saudimirror.com/dante-labs-selected-to-provide-genetic-testing-for-abu-dhabi-stem-cells-center-jointly-developing-mrna-cancer-vaccines/ Thu, 28 Apr 2022 01:00:00 +0000 http://www.saudimirror.com/?p=214701 NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, is pleased to announce the company has been selected as the genetic testing provider for Abu Dhabi Stem Cells Center (ADSCC), the Abu Dhabi–based specialist healthcare center focused on cell therapy and regenerative medicine. In parallel, a joint R&D program has been launched focused on the development of a mRNA vaccine platform to identify individual cancer treatments.

    "This collaboration with ADSCC is an important step forward in our strategy to provide the best clinical genetic services now to United Arab Emirates and in the Region. The goal is that partnerships like this will pave the way to a much wider adoption of genomics in additional clinical fields," said Andrea Riposati, CEO of Dante Labs. "It is clear that the UAE has become a global leader in the field of genomics, and we are pleased to invest in this innovative country.''

    Effective April 18, 2022, Dante has begun providing clinical genetic testing to ADSCC patients covering a wide spectrum of medical specializations and all testing will take place in Dante's new Dubai laboratory.

    "We are very excited and are looking forward to our upcoming collaboration with Dante," said Dr. Yendry Ventura Carmenate, General Manager at ADSCC. "The combined experience of the professionals at the helm of this collaboration gives us absolute assurance in the success of this very ambitious endeavor. Working together with Dante Labs provides us with an excellent opportunity to further boost the status of United Arab Emirates as the worldwide leader in both genomics and innovative healthcare practices, aimed at the eradication of deadly diseases throughout the world for the greater good of humanity."

    In addition to genomic testing services, Dante and the ADSCC will partner on the launch of an R&D program with a focus on personalized treatments for oncology patients, and eventually the development of cancer vaccines.

    “The hope with testing programs like ours with ADSCC is that it will pave the way for wider adoption of genomes in other areas such as R&D and training programs," said Professor Mattia Capulli, Chief Scientific Officer of Dante Laboratories. "The mRNA technology is extremely promising for infectious diseases. We are convinced that the joint R&D program will deliver solid results in oncology treatments very soon and will lead to new types of vaccines in oncology and other clinical areas."

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    About Abu Dhabi Stem Cells Center (ADSCC)

    Abu Dhabi Stem Cells Center (ADSCC) is an Abu Dhabi–based specialist healthcare center focused on cell therapy and regenerative medicine techniques, as well as delivering cutting–edge research on stem cells in the region.

    The Center was founded in March 2019 to meet growing domestic and regional demand for highly specialized medical services and treatments. Equipped with the latest technologies, medical devices which are unique to the region, and a team of internationally recognized doctors working hand in hand with researchers, ADSCC is the first of its kind in the UAE.

    The Center focuses primarily on harvesting, processing, characterizing and storing cell products for clinical application in both regenerative medicine and hematopoietic transplantation. It aims to streamline and develop new processes related to stem cell therapy and research, in order to both serve our team of doctors' clinical needs and become a referral center for the region.

    Contacts:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.comI'm +39 0862 191 0671
    www.dantelabs.com

    info@adscc.ae
    Abu Dhabi Stem Cells Center

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/76811dae–c095–4504–a5b6–34da0ca44892


    GLOBENEWSWIRE (Distribution ID 8530342)

    ]]>
    Dante Labs announces ventures into biosimulation and drug discovery, demonstrating the predictive value of the Dante Platform http://www.saudimirror.com/dante-labs-announces-ventures-into-biosimulation-and-drug-discovery-demonstrating-the-predictive-value-of-the-dante-platform/ Mon, 11 Apr 2022 11:30:00 +0000 http://www.saudimirror.com/?p=213808 NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomic information and precision medicine, announces new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform.

    "Often the first concern from patients after they receive a diagnosis through whole genome sequencing is what therapies are available to treat their condition. In an effort to address this issue, Dante Labs decided to create and invest in a drug discovery R&D program," said Andrea Riposati, CEO of Dante Labs. "We are uniquely positioned to deliver more complete medical solutions from whole genome sequencing and diagnosis through drug discovery and the development of therapies for patients."

    Dante's integrated approach to data, software and AI has enabled the Company to develop a biosimulation platform based on Dante's database of genomic and medical data. The platform predicts changes in viruses and is being used by Dante to simulate future variants of the SARS–CoV2 virus responsible for COVID–19. Dante has an existing patent portfolio surrounding its mRNA and iRNA technology and continues to invest and develop additional patents.

    Dante's venture into biosimulation, which is anchored in whole genome sequencing data, supports the development of therapies and drugs, delivering a more personalized, holistic approach to medicine. This computational approach to the design of new drug programs is foundational to the Company's efforts to deliver end–to–end solutions to people for which there are currently limited or no therapies to treat their conditions.

    Since its foundation, Dante has financed a broad R&D program with the aim to create the first end–to–end solution from diagnosis to therapy with a strong focus on rare diseases and with the ambition to export the model to other disease areas like cancer in the near future. In the past two quarters alone, Dante Labs has advanced its drug programs in muscle rare disease, neurological rare disease and immunology into the pre–clinical phase. Additionally, Dante has launched four new drug programs in co–development with external partners in COVID, oncology and degenerative disease.

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantelabs.com


    GLOBENEWSWIRE (Distribution ID 8519931)

    ]]>
    Dante Labs announces ventures into biosimulation and drug discovery, demonstrating the predictive value of the Dante Platform http://www.saudimirror.com/dante-labs-announces-ventures-into-biosimulation-and-drug-discovery-demonstrating-the-predictive-value-of-the-dante-platform/ Mon, 11 Apr 2022 11:30:00 +0000 http://www.saudimirror.com/?p=213809 NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomic information and precision medicine, announces new genomic driven biosimulation and significant progress made to its drug discovery program, demonstrating the value of the Dante Platform.

    "Often the first concern from patients after they receive a diagnosis through whole genome sequencing is what therapies are available to treat their condition. In an effort to address this issue, Dante Labs decided to create and invest in a drug discovery R&D program," said Andrea Riposati, CEO of Dante Labs. "We are uniquely positioned to deliver more complete medical solutions from whole genome sequencing and diagnosis through drug discovery and the development of therapies for patients."

    Dante's integrated approach to data, software and AI has enabled the Company to develop a biosimulation platform based on Dante's database of genomic and medical data. The platform predicts changes in viruses and is being used by Dante to simulate future variants of the SARS–CoV2 virus responsible for COVID–19. Dante has an existing patent portfolio surrounding its mRNA and iRNA technology and continues to invest and develop additional patents.

    Dante's venture into biosimulation, which is anchored in whole genome sequencing data, supports the development of therapies and drugs, delivering a more personalized, holistic approach to medicine. This computational approach to the design of new drug programs is foundational to the Company's efforts to deliver end–to–end solutions to people for which there are currently limited or no therapies to treat their conditions.

    Since its foundation, Dante has financed a broad R&D program with the aim to create the first end–to–end solution from diagnosis to therapy with a strong focus on rare diseases and with the ambition to export the model to other disease areas like cancer in the near future. In the past two quarters alone, Dante Labs has advanced its drug programs in muscle rare disease, neurological rare disease and immunology into the pre–clinical phase. Additionally, Dante has launched four new drug programs in co–development with external partners in COVID, oncology and degenerative disease.

    About Dante Labs

    Dante Labs is a global genomic information company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. The Company uses its platform to deliver better patient outcomes from diagnostics to therapeutics with assets including one of the largest private genome databases with research consent, proprietary software designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantelabs.com


    GLOBENEWSWIRE (Distribution ID 8519931)

    ]]>
    Dante Labs establishes the first of its Regional Medical Genomics Boards in Europe made of national and multinational world leaders in genomics http://www.saudimirror.com/dante-labs-establishes-the-first-of-its-regional-medical-genomics-boards-in-europe-made-of-national-and-multinational-world-leaders-in-genomics/ Thu, 24 Mar 2022 11:30:00 +0000 http://www.saudimirror.com/?p=214803 NEW YORK, March 24, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, announces the establishment of the first of its Medical Genomics Boards, strengthening the Company's mission and research activity in this new frontier of healthcare, using genomics to promote prevention and treatment.

    The Medical Genomics Board is made up of world leaders in genomics with multidisciplinary expertise with scientists and qualified genomics professionals, including geneticists, molecular biochemists and clinical experts in pharmacogenomics, nutrigenomics and oncogenomics, prenatal, neonatal and pediatric rare diseases.

    “The goal is to pursue the path of personalized therapeutic maps through the organization of a clear reporting system despite the great complexity of the data deriving from the whole genome sequencing in NGS," said Andrea Riposati, CEO of Dante Labs. "It is Dante's intention to establish more of these regional Medical Genomics Boards around the world to bring genomics to the forefront of precision medicine in healthcare, taking into account the regional and cultural considerations of each area."

    The first round table of the newly formed Committee was held on March 10th, 2022 in Castel Gandolfo. The establishment of the Board was made official at that time. The role of Scientific Director has been entrusted to prof. Giuseppe Novelli, a scholar of multifactorial genetic diseases, who will coordinate the activities of the board and will be a technical–scientific consultant.

    The members of the Board all come from medical and academia backgrounds, including doctors, pharmacists and biologists. These experts in Omic sciences were chosen to cover all therapeutic areas, from oncogenomics to pharmacogenomics. Specifically, they include Professor in dermatology at the Sapienza University of Rome, Giovanni Pellacani; Professor Laura di Renzo, from the Tor Vergata Polyclinic in Rome where she deals with nutrigenetics and nutrigenomics; Professor in clinical biochemistry and molecular biology at the University of Tor Vergata, Sergio Bernardini; Professor Antonio Novelli, who deals with genomics in prenatal diagnosis at the Bambino Ges Children's Hospital in Rome; Professor in Internal Medicine at the Sapienza University of Rome, Salvatore Minisola. Dr. Camilla Nero, expert on oncogenomics from the Catholic University of Rome.

    About Dante Labs

    Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantelabs.com


    GLOBENEWSWIRE (Distribution ID 8509129)

    ]]>
    Dante Labs unveils Dante Genomics, the Company’s B2B global online marketplace delivering genomic solutions for medical professionals, researchers and pharma http://www.saudimirror.com/dante-labs-unveils-dante-genomics-the-companys-b2b-global-online-marketplace-delivering-genomic-solutions-for-medical-professionals-researchers-and-pharma/ Mon, 14 Mar 2022 11:30:00 +0000 http://www.saudimirror.com/?p=213835 NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) — Dante Labs, a global leader in genomics and precision medicine, today announced the launch of Dante Genomics, an online marketplace portal specifically dedicated to healthcare providers, clinics, researchers and governments which will offer advanced genomic services for research and clinical applications.

    This unique marketplace will be the first of its kind in the industry and will provide an intuitive and dynamic experience for customers worldwide. Customers will have the opportunity to choose among several sequencing technologies and options and get a tailored and personalized solution.

    "At Dante, we are continually working to provide better genomic solutions to our customers," said Andrea Riposati, CEO of Dante Labs. "With the launch of this new online marketplace, Dante Genomics will make it as easy for clinical professionals and researchers to complete their genomics projects as it is to buy a book or tool on Amazon."

    As a Sr. Product Manager in Seattle, Andrea Riposati belonged to the original Amazon team that developed Amazon Business, the Amazon.com ($AMZN) B2B portal that revolutionized industrial and scientific supplies in 2014.

    Dante Genomics also provides a transparent pricing model to empower partners to get a personalized quote, while simultaneously purchasing online with a choice of the best deals to suit their specific needs.

    The portal hosts a wide range of genomic services, from whole genome sequencing to non invasive prenatal diagnostics. All the services offered are suitable for either research or clinical applications.

    Dante Labs recognizes that online B2B buying experiences in the healthcare industry is the need of millions of organizations. Dante Genomics has been designed for a user–friendly experience and has been optimized with easy navigation for desktop and mobile devices. The platform allows for order queries to be addressed online and is supported by secure payment methods and is compliant with the General Data Protection Regulation (GDPR).

    Dante Genomics B2B customers have access to premium services including:

    • 1 week turnaround time on most tests
    • Oncology and germline sequencing tests
    • Custom projects
    • Multi–platform sequencing

    Clinical and research customers will benefit from B2B features, including:

    • Quote Requests
    • Payment method visibility control (including PO payment option)
    • Quick Order Pad (including CSV upload)
    • Bulk discount
    • Invoicing and payment via wire transfer
    • Multiple currencies
    • Flexible buyer–side user management: several layers of roles and permissions (including Super Admin, Company Admin, Sr. Buyer, Jr. Buyer)

    Access the Dante Genomics store at shop.dantegenomics.com to learn more.

    About Dante Labs

    Dante Labs is a global genomic data company building and commercializing a new class of transformative health and longevity applications based on whole genome sequencing and AI. Our assets include one of the largest private genome databases with research consent, a proprietary software platform designed to unleash the power of genomic data at scale and proprietary processes which enable an industrial approach to genomic sequencing.

    Contact:

    Laura D'Angelo
    VP of Investor Relations
    ir@dantelabs.com
    +39 0862 191 0671
    www.dantelabs.com


    GLOBENEWSWIRE (Distribution ID 8502435)

    ]]>